Middle East & Africa Gastroparesis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Idiopathic, Diabetic, Post-Surgical, and Others), Drug Class (Prokinetic Agents, Botulinum Toxin Injections, and Antiemetic Agents), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others)
Market Introduction
MEA consists of three major countries namely United Arab Emirates (UAE), Saudi Arabia and South Africa. Saudi Arabia is the largest market for gastroparesis. The market is driven by extensive research projects undertaken by a number of research institutes, rising prevalence of gastroparesis, and availability of infrastructure and facilities for research in UAE and Saudi Arabia. Rest of MEA include countries such as, Israel, Iran, Iraq, Kuwait, Oman, Egypt, Kenya, and others. Rising focus of development of innovative therapies for the treatment of gastrointestinal diseases across the region is expected to offer a lucrative opportunity for the growth of the market. Moreover, the government in the region are actively investing in the research and development in collaboration with international players to boost drug discovery for gastroparesis in the region. Such strategic steps by the government authorities are estimated to drive the growth of rest of MEA gastroparesis market during the forecast period.
The COVID-19 has shown substantial effects in MEA. The COVID-19 pandemic has caused massive disruptions to global supply chains and affected the research and development activities in these countries in 2020. The companies are preferring non-physical marketing campaigns and shifting sales processes online. The COVID-19 has affected the sales of essential OTC drugs such as anti-emetic and prokinetic drugs. Moreover, the exports and imports of pharmaceutical products are returning to their original momentum. Thus, the availability of the products in the region is improving. Therefore, the growth in African pharmaceuticals is likely to boost the development of the anti-emetic drugs in market. For instance, in May 2020, the Vice president of global health stated in a blog post of Africa program, “The African Medicines Agency (AMA), a continental effort to harmonize medicines regulation, should be fully approved and rapidly scaled up to advance regulatory dependence, mutual recognition, and risk-based regulatory practices. The AMA will also help and support in the production of active ingredients in Africa, streamline market access, and reduce barriers to market entry for manufacturers.
Get more information on this report :
Market Overview and Dynamics
The gastroparesis market in MEA is expected to grow from US$ 230.20 million in 2020 to US$ 278.36 million by 2027; it is estimated to grow at a CAGR of 2.8% from 2020 to 2027. Gastric emptying is associated with the coordination among the motor activity of proximal stomach, distal stomach, and duodenum. These internal organs are controlled by the feedback mechanism from neural signals generated through the interaction between nutrients and small intestine. Aging leads to diminished homeostatic regulations of physiologic functions, along with the slowing of gastric emptying. Moreover, it influences motor and sensory functions. In addition, geriatric population is highly vulnerable to gastroparesis due to factors such as the poor oral medication absorption, inadequate appetite regulation, and postprandial glycemia. According to the 2019 revision of World Population Prospects, 1 in 6 people would be aged more than 65 by 2050, with an increase from 1 in 11 in 2019. Thus, the continuous increase in aging population and issues associated with gastric emptying among the elderly population drive the gastroparesis market.
Key Market Segments
The MEA gastroparesis market is segmented on the basis of type, drug class, distribution channel, and country. The MEA gastroparesis market, by type, is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019. The MEA gastroparesis market, by drug class type, is segmented into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment held the largest share of the market in 2019. Based on distribution channel, the MEA gastroparesis market is segmented into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019. Based on country, the MEA gastroparesis market is segmented into Saudi Arabia, South Africa, UAE, and rest of MEA. Saudi Arabia held the largest market share in 2019.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the gastroparesis market in MEA are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Allergan Plc; Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.); Ipca Laboratories Ltd.; Johnson and Johnson Services, Inc.; Pfizer Inc.; and TEVA PHARMACEUTICAL INDUSTRIES LTD.
Reasons to buy report
- To understand the MEA gastroparesis market landscape and identify market segments that are most likely to guarantee a strong return.
- Stay ahead of the race by comprehending the ever-changing competitive landscape for MEA gastroparesis market.
- Efficiently plan M&A and partnership deals in MEA gastroparesis market by identifying market segments with the most promising probable sales.
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form MEA gastroparesis market.
- Obtain market revenue forecast for market by various segments from 2021-2028 in MEA region.
MEA Gastroparesis Market Segmentation
MEA Gastroparesis Market - By Type
- Idiopathic
- Diabetic
- Post-surgical
- Others
MEA Gastroparesis Market - By Drug Class
- Prokinetic Agents
- Botulinum Toxin Injections
- Antiemetic Agent
MEA Gastroparesis Market – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
MEA Gastroparesis Market - By Country
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
MEA Gastroparesis Market - Company Profiles
- Allergan Plc
- Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
- Ipca Laboratories Ltd.
- Johnson and Johnson Services, Inc.
- Pfizer Inc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Gastroparesis Market – By Type
1.3.2 MEA Gastroparesis Market – By Drug Class Type
1.3.3 MEA Gastroparesis Market – By Distribution Channel
1.3.4 MEA Gastroparesis Market – By Country
2. MEA Gastroparesis Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Gastroparesis Market – Market Landscape
4.1 Overview
4.2 MEA PEST Analysis
4.3 Expert Opinion
5. MEA Gastroparesis Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Diabetes Mellitus Prevalence Is Increasing
5.1.2 Surge in Geriatric Population
5.2 Market Restraints
5.2.1 After Effects of Gastroparesis Drugs
5.3 Market Opportunities
5.3.1 Research Work Getting Financial Assistance
5.4 Future Trends
5.4.1 Gastric Electrical Stimulation Therapy Research Getting More Attention
5.5 Impact Analysis
6. Gastroparesis Market – MEA Analysis
6.1 MEA Gastroparesis Market Revenue Forecast and Analysis
7. MEA Gastroparesis Market Analysis – By Type
7.1 Overview
7.2 MEA Gastroparesis Market Revenue Share, by Type (2019 and 2027)
7.3 Idiopathic
7.3.1 Overview
7.3.2 Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Diabetic
7.4.1 Overview
7.4.2 Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.5 Post-Surgical
7.5.1 Overview
7.5.2 Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8. MEA Gastroparesis Market Analysis – By Drug Class Type
8.1 Overview
8.2 MEA Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)
8.3 Prokinetic Agents
8.3.1 Overview
8.3.2 Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Botulinum Toxin Injection
8.4.1 Overview
8.4.2 Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Antiemetic Agents
8.5.1 Overview
8.5.2 Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9. MEA Gastroparesis Market Analysis – By Distribution Channel
9.1 Overview
9.2 MEA Gastroparesis Market Share, by Distribution Channel, 2019 and 2027, (%)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Hospital Pharmacies
9.4.1 Overview
9.4.2 Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
10. MEA Gastroparesis Market – Country Analysis
10.1 Overview
10.1.1 MEA: Gastroparesis Market, by Country, 2019 & 2027 (%)
10.1.2 Saudi Arabia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.2.1 Saudi Arabia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.2.2 Saudi Arabia Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.2.3 Saudi Arabia Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.2.4 Saudi Arabia Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.3 UAE: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.1 UAE: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.2 UAE Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.3.3 UAE Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.3.4 UAE Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.4 South Africa: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.1 South Africa: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.2 South Africa Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.4.3 South Africa Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.4.4 South Africa Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.4.5 Rest of MEA: Gastroparesis Market - Revenue and Forecasts to 2027 (USD Million)
10.1.4.6 Rest of MEA: Gastroparesis Market- Revenue and Forecasts to 2027 (USD Million)
10.1.4.7 Rest of MEA Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.4.8 Rest of MEA Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.4.9 Rest of MEA Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
11. Impact of COVID-19 Pandemic on MEA Gastroparesis Market
11.1 MEA: Impact Assessment of COVID-19 Pandemic
12. Gastroparesis Market –Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Gastroparesis Market, 2018-2020
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Allergan Plc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Bausch Health Companies Inc. (Salix Pharmaceuticals)
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Johnson and Johnson Services, Inc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Pfizer Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Ipca Laboratories Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
14. Appendix
14.1 About the Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Saudi Arabia Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 2. Saudi Arabia Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 3. Saudi Arabia Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 4. UAE Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 5. UAE Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 6. UAE Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 7. South Africa Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 8. South Africa Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 9. South Africa Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 10. Rest of MEA Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 11. Rest of MEA Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 12. Rest of MEA Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 13. Recent Inorganic Growth Strategies in the Gastroparesis market
Table 14. Glossary of Terms, Gastroparesis Market
LIST OF FIGURES
Figure 1. MEA Gastroparesis Market Segmentation
Figure 2. MEA Gastroparesis Market Segmentation, By Country
Figure 3. MEA Gastroparesis Market Overview
Figure 4. Idiopathic Segment Held Largest Share of MEA Gastroparesis Market
Figure 5. Saudi Arabia to Show Remarkable Growth During Forecast Period
Figure 6. MEA PEST Analysis
Figure 7. MEA Gastroparesis Market Impact Analysis of Drivers and Restraints
Figure 8. MEA Gastroparesis Market – Revenue Forecast And Analysis – 2019- 2027
Figure 9. MEA Gastroparesis Market Revenue Share, by Type (2019 and 2027)
Figure 10. MEA Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 11. MEA Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 12. MEA Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 13. MEA Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 14. MEA Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)
Figure 15. MEA Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 16. MEA Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 17. MEA Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 18. MEA Gastroparesis Market Share, by Distribution Channel, 2019 and 2027 (%)
Figure 19. MEA Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 20. MEA Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. MEA Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 22. MEA: Gastroparesis Market, by Key Country – Revenue (2019) (US$ Million)
Figure 23. MEA: Gastroparesis Market, by Country, 2019 & 2027 (%)
Figure 24. Saudi Arabia: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 25. UAE: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 26. South Africa: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 27. Rest of MEA: Gastroparesis Market- Revenue And Forecasts To 2027 (USD Million)
Figure 28. Impact Of COVID-19 Pandemic in MEA Market
Figure 29. Growth Strategies in the Gastroparesis Market, 2018-2020
- Allergan Plc
- Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
- Ipca Laboratories Ltd.
- Johnson and Johnson Services, Inc.
- Pfizer Inc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA gastroparesis market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the MEA gastroparesis market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the gastroparesis market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution